A Case to Support the Continued Use of Rifampin in Clinical Drug-Drug Interaction Studies
Clin Pharmacol Ther
.
2024 Mar 18.
doi: 10.1002/cpt.3256.
Online ahead of print.
Authors
Joel P Bercu
1
,
David J Ponting
2
,
Sharon L Ripp
3
,
Krista L Dobo
4
,
Rheem A Totah
5
,
Jayaprakasam Bolleddula
6
Affiliations
1
Gilead Sciences, Inc., Nonclinical Safety and Pathobiology (NSP), Foster City, California, USA.
2
Lhasa Limited, Leeds, UK.
3
Pharmacokinetics, Dynamics & Metabolism, Pfizer Research & Development, Groton, Connecticut, USA.
4
Drug Safety Research and Development, Pfizer Research & Development, Groton, Connecticut, USA.
5
Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA.
6
Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.
PMID:
38494918
DOI:
10.1002/cpt.3256
No abstract available